Patent US3898981A successfully refreshed from Google Patents.
Patent US4976950A successfully refreshed from Google Patents.
US4976950A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bone marrow suppressing agents
Assignee: Dow Chemical Co
•
Filing: 1989-11-13
•
Granted: 1990-12-11
•
Expires: 2009-11-13
Abstract
Abstract The invention concerns a method for suppressing bone marrow which comprises administering to a mammal at least one bone marrow suppressing complex of a radionuclide selected from the group consisting of Samarium-153, Gadolinium-159, Holmium-166 and Yttrium-90 and at least one macrocyclic aminophosphonic acid ligand containing the 1,4,7,10-tetraazacyclododecane moiety, or a physiologically acceptable salt thereof. Suitable compositions for use in this method are also provided.
Inventors
- 👤 Jaime Simon
- 👤 Joseph R. Garlich
- 👤 David A. Wilson
- 👤 Kenneth McMillan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 22:58
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0474; A61K51/0482; A61K2121/00
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
70 words
A method for suppressing bone marrow which comprises administering to a mammal in need of such treatment a bone marrow suppressing amount of a bone marrow suppressing composition comprising the radionuclide Yttrium-90 complexed with at least one macrocyclic aminophosphonic acid ligand containing a 1,4,7,10-tetraazacylododecane moiety and wherein the phosphonic acid functionality is attached to the nitrogen of the macrocyclic polyamine through an alkylene group or a physiologically acceptable salt thereof.
Claim 2
Independent Claim
70 words
A method for suppressing bone marrow which comprises administering to a mammal in need of such treatment a bone marrow suppressing amount of a bone marrow suppressing composition comprising the radionuclide Yttrium-90 complexed with at least one macrocyclic aminophosphonic acid ligand containing a 1,4,7,10-tetraazacylododecane moiety and wherein the phosphonic acid functionality is attached to the nitrogen of the macrocyclic polyamine through an alkylene group or a physiologically acceptable salt thereof.
Claim 3
Dependent Claim
17 words
The method of claim 1 wherein the ligand is 1,4,7,10-tetraazacyclododecanetetrmethylenephosphonic acid or a physiologically acceptable salt thereof.
Claim 4
Dependent Claim
43 words
The method of claim 1 used in conjunction with an additional treatment regimen using at least one of (a) one or more bone marrow suppressing agents, and/or (b) one or more chemotherapeutic agents, and/or (c) one or more radiotherapeutic agents or radiotherapeutic methods.
Claim 5
Dependent Claim
16 words
The method of claim 1 used in conjunction with total body irradiation or targeted external irradiation.
Claim 6
Dependent Claim
20 words
The method of claim 1 including the additional step of bone marrow transplantation after sufficient bone marrow suppression is achieved.
Claim 7
Dependent Claim
17 words
The method of claim 1 used in conjunction with a treatment employing at least one chemotherapeutic agent.
Claim 8
Dependent Claim
21 words
The method of claim 6 wherein the chemotherapeutic agent is selected from dimethyl busulfan, cyclophosphamide, bischloroethyl nitrosourea, cytosine arabinoside, and 6-thioguanine.
Claim 9
Dependent Claim
22 words
The method of claim 1 used in conjunction with total body irradiation and with a treatment employing at least one chemotherapeutic agent.
Claim 10
Dependent Claim
21 words
The method of claim 8 wherein the chemotherapeutic agent is selected from dimethyl busulfan, cyclophosphamide, bischloroethyl nitrosourea, cytosine arabinoside, and 6-thioguanine.
Claim 11
Dependent Claim
24 words
The method of claim 1 used in conjunction with one or more therapeutic regimens for the treatment of leukemia, lymphoma, myeloma or Hodgkin's disease.
Claim 12
Dependent Claim
13 words
The method of claim 10 wherein the disease being treated is a leukemia.
Claim 13
Dependent Claim
13 words
The method of claim 10 wherein the disease being treated is a lymphoma.
Claim 14
Dependent Claim
13 words
The method of claim 10 wherein the disease being treated is a myeloma.
Claim 15
Dependent Claim
13 words
The method of claim 10 wherein the disease being treated is Hodgkin's disease.
Claim 16
Dependent Claim
80 words
A sterile composition suitable for administration to a mammal for suppressing bone marrow comprising the radionuclide Yttrium-90 complexed with at least one macrocycle aminophosphonic acid ligand containing the 1,4,7,10-tetraazacyclododecane moiety or a physiologically acceptable salt thereof, wherein the phosphorous of said ligand is attached to the amine nitrogen through an alkylene moiety and wherein the radionuclide in dosage form is present in an amount containing from about 18 to about 1850 megabecquerels per kilogram of body weight of said mammal.
Claim 17
Dependent Claim
80 words
A sterile composition suitable for administration to a mammal for suppressing bone marrow comprising the radionuclide Yttrium-90 complexed with at least one macrocycle aminophosphonic acid ligand containing the 1,4,7,10-tetraazacyclododecane moiety or a physiologically acceptable salt thereof, wherein the phosphorous of said ligand is attached to the amine nitrogen through an alkylene moiety and wherein the radionuclide in dosage form is present in an amount containing from about 18 to about 1850 megabecquerels per kilogram of body weight of said mammal.
Claim 18
Dependent Claim
16 words
The composition of claim 15 wherein the ligand to radionuclide ratio is from 1:1 to 2:1.
Claim 19
Dependent Claim
14 words
A pharmaceutical formulation comprising the composition of claim 15 in a pharmaceutically acceptable carrier.
Claim 20
Dependent Claim
25 words
The composition of claim 15 wherein the dosage form contains from about 185 to about 1850 mega-becquerels per kilogram of body weight of said mammal.
Claim 21
Dependent Claim
12 words
The composition of claim 18 wherein the macrocyclic ligand is 1,4,7,10-tetraazacylododecanetetramethylenephosphonic acid.
Claim 22
Dependent Claim
12 words
The composition of claim 15 wherein the macrocyclic ligand is 1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid.
Claim 23
Dependent Claim
14 words
A pharmaceutical formulation comprising the composition of claim 20 in a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
US4508625A
Cited
EP0164843A2
Cited
US4898724A
Cited
US4678667A
Cited
EP0291605A2
Cited
US4853209A
Cited
US4882142A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-12-10 | 1994-06-11 | 1994-12-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-12-10 | 1998-06-11 | 1998-12-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-12-10 | 2002-06-11 | 2002-12-11 | $7700.00 | Window Closed / Lapsed |